Lung Cancer

Stay updated with news from ASCO’s official conference reporter.
April 28, 2022
A comprehensive multidisciplinary approach is crucial to accurately diagnosing and optimally managing immune-related adverse events in patients with metastatic non–small cell lung cancer.
April 13, 2022
The KRYSTAL-1 trial was the first-in-human study of the oral KRAS G12C inhibitor adagrasib, which confirmed partial responses in some patients with KRAS G12C–mutant non–small cell lung cancer and colorectal cancer.
March 30, 2022
USPSTF guidelines have been updated to recommend the use of low-dose computed tomography and expand the criteria for lung cancer screening, aiming to reduce mortality (through more early detection) and ameliorate racial disparities in screening. Despite these updates, screening rates remain low.
March 15, 2022
Adding toripalimab to first-line chemotherapy in patients with advanced non–small cell lung cancer provided superior PFS and OS compared to chemotherapy alone with a manageable safety profile.
February 23, 2022
Adjuvant platinum-based chemotherapy has been the standard-of-care treatment for resected stage IB to III lung cancer with a modest survival benefit.
February 16, 2022
A rapid recommendation update to an ASCO guideline offers revised parameters for adjuvant therapy in patients with resected non–small cell lung cancer (NSCLC) who have stage IB to IIIA disease.
January 26, 2022
Targeted therapies have improved outcomes for patients with advanced non–small cell lung cancer (NSCLC) who harbor mutations in EGFR, ALK, ROS1, RET, NTRK, and KRAS, and those with MET exon 14 skipping mutations; targeted agents represent the standard of care for these patients.
January 19, 2022
The identification of molecularly defined subsets in non–small cell lung cancer (NSCLC) and the subsequent development of specific targeted therapies (tyrosine kinase inhibitors [TKIs], small molecules, and monoclonal antibodies) have dramatically improved treatment outcomes for patients with these defined molecular alterations.
December 23, 2021
A new ASCO guideline provides key recommendations for the evaluation and management of stage III non–small cell lung cancer (NSCLC).
October 27, 2021
Is there a role for upfront immunotherapy-based systemic therapy before local therapy for patients with asymptomatic brain metastases from non–small cell lung cancer?

This site is intended for healthcare professionals in Europe and Japan only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

Before you go....

We'd love your feedback!

Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.